At a glance
- Originator Nonindustrial source
- Developer PharmaMar
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 07 Oct 1999 Preclinical development for Cancer in Spain (Unknown route)
- 09 Sep 1998 Profile reviewed
- 09 Sep 1998 No-Development-Reported for Cancer in Spain (Unknown route)